60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

Cancer Research
Nicoletta CieriCatherine J Wu

Abstract

The year 2020 marked the 30th anniversary of the Nobel Prize in Medicine awarded to E. Donnall Thomas for the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat hematologic malignancies and other blood disorders. Dr. Thomas, "father of bone marrow transplantation," first developed and reported this technique in 1957, and in the ensuing decades, this seminal study has impacted fundamental work in hematology and cancer research, including advances in hematopoiesis, stem cell biology, tumor immunology, and T-cell biology. As the first example of cancer immunotherapy, understanding the mechanisms of antitumor biology associated with allo-HSCT has given rise to many of the principles used today in the development and implementation of novel transformative immunotherapies. Here we review the historical basis underpinning the development of allo-HSCT as well as advances in knowledge obtained by defining mechanisms of allo-HSCT activity. We review how these principles have been translated to novel immunotherapies currently utilized in clinical practice and describe potential future applications for allo-HSCT in cancer research and development of novel therapeutic strategies.

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Sep 13, 1979·The New England Journal of Medicine·E D ThomasP L Weiden
Jan 1, 1988·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·C RudeF Haslev
Jan 1, 1968·Transplantation·R B EpsteinE D Thomas
Sep 4, 1980·The New England Journal of Medicine·J A HansenE R Giblett
Jun 18, 1981·The New England Journal of Medicine·P L WeidenUNKNOWN Seattle Marrow Transplant Team
May 3, 2000·The Journal of Clinical Investigation·B NikolicM Sykes
Dec 5, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Robert J SoifferJerome Ritz
May 14, 2003·The Journal of Experimental Medicine·Makoto MurataStanley R Riddell
Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bruce R BlazarPatricia A Taylor
Mar 10, 1956·Nature·C E FORDJ F LOUTIT
Aug 1, 1956·Proceedings of the Society for Experimental Biology and Medicine·J J TRENTIN
Sep 12, 1957·The New England Journal of Medicine·E D THOMASJ W FERREBEE
Oct 24, 1962·Annals of the New York Academy of Sciences·D W BARNESH S MICKLEM
Nov 30, 1964·Annals of the New York Academy of Sciences·E D THOMASJ W FERREBEE
Dec 10, 2003·Experimental Hematology·Warren D Shlomchik
Oct 4, 2005·Nature Reviews. Immunology·Kristin A HogquistStephen C Jameson
Apr 20, 2006·Nature Reviews. Immunology·Luca GattinoniNicholas P Restifo
Nov 30, 2006·Annual Review of Immunology·Lisbeth A WelniakWilliam J Murphy
Apr 1, 1949·Proceedings of the Society for Experimental Biology and Medicine·L O JACOBSON, E K MARKS
Dec 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Adrian J C BloorStephen Mackinnon
Dec 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Udo F HartwigWolfgang Herr
May 21, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Leo LuznikEphraim J Fuchs
Aug 8, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M R BishopD H Fowler
Oct 23, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Claudia CalcaterraAndrea Balsari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.